Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 11, 2014, Pages 901-910

  Yki Järvinen, Hannele ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ABDOMINAL OBESITY; AGE DISTRIBUTION; CARDIOVASCULAR DISEASE; CHOLESTEROL STONE; ECHOGRAPHY; END STAGE LIVER DISEASE; ETHNIC DIFFERENCE; FAMILY HISTORY; GENE; GENETIC VARIABILITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHYSICAL INACTIVITY; PNPLA3 GENE; REVIEW; SLEEP DISORDERED BREATHING; SUGAR INTAKE; THROMBOEMBOLISM; COMPLICATION; FATTY LIVER; FEMALE; GENETICS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; LIPASE; MALE; MEMBRANE PROTEINS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RISK FACTORS;

EID: 84902672359     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70032-4     Document Type: Review

References (115)

1. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010, 53:600-605.
2. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645. the International Diabetes Federation Task Force on Epidemiology and Prevention, the National Heartthe National Heart, LungLung, Blood InstituteBlood Institute, the American Heart Associationthe American Heart Association, the World Heart Federationthe World Heart Federation, the International Atherosclerosis Societythe International Atherosclerosis Society, the International Association for the Study of Obesitythe International Association for the Study of Obesity.
3. Reaven GM Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
4. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007, 92:3490-3497.
5. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142:1592-1609. the American Gastroenterological Association, the American Association for the Study of Liver Diseasesthe American Association for the Study of Liver Diseases, the American College of Gastroenterologyhthe American College of Gastroenterologyh.
6. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002, 87:3023-3028.
7. Adiels M, Westerbacka J, Soro-Paavonen A, et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007, 50:2356-2365.
8. Anstee QM, Targher G, Day CP Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013, 10:330-344.
9. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009, 35:277-287.
10. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
11. Clark JM, Brancati FL, Diehl AM The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
12. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011, 53:810-820. the NASH Clinical Research Network (CRN).
13. Vernon G, Baranova A, Younossi ZM Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
14. Starley BQ, Calcagno CJ, Harrison SA Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
15. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141:1249-1253.
16. Torres DM, Harrison SA Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 2012, 32:30-38.
17. Yu J, Shen J, Sun TT, Zhang X, Wong N Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol 2013, 23:483-491.
18. Trépo E, Nahon P, Bontempi G, et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 2013, published online Oct 1. 10.1002/hep.26767.
19. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005, 288:E462-E468.
20. Koehler EM, Schouten JN, Hansen BE, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol 2012, 57:1305-1311.
21. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994. Am J Epidemiol 2013, 178:38-45.
22. Patton HM, Yates K, Unalp-Arida A, et al. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol 2010, 105:2093-2102.
23. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009, 51:371-379.
24. Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol 2010, 105:336-344.
25. Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013, 59:550-556. the LIDO Study Group.
26. Choi JH, Rhee EJ, Bae JC, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013, 44:115-120.
27. Park SK, Seo MH, Shin HC, Ryoo JH Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013, 57:1378-1383.
28. Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52:1056-1060.
29. Yki-Järvinen H Pathophysiology of type 2 diabetes. Oxford Textbook of Endocrinology and Diabetes 2011, 1740-1748. Oxford University Press, Oxford. J.A.H. Wass, P.M. Stewart (Eds.).
30. Chen LY, Qiao QH, Zhang SC, Chen YH, Chao GQ, Fang LZ Metabolic syndrome and gallstone disease. World J Gastroenterol 2012, 18:4215-4220.
31. Nervi F, Arrese M Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences?. Am J Gastroenterol 2013, 108:959-961.
32. Simonen P, Kotronen A, Hallikainen M, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011, 54:153-159.
33. Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012, 15:665-674.
34. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007, 133:496-506.
35. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008, 134:424-431.
36. Adiels M, Olofsson SO, Taskinen MR, Borén J Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
37. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 2008, 135:122-130.
38. Tchernof A, Després JP Pathophysiology of human visceral obesity: an update. Physiol Rev 2013, 93:359-404.
39. Sung KC, Wild SH, Byrne CD Development of new fatty liver, or resolution of existing fatty liver, over five years of follow up, and risk of incident hypertension. J Hepatol 2014, published online Jan 18. 10.1016/j.jhep.2014.01.009.
40. Lehto S, Rönnemaa T, Pyörälä K, Laakso M Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes. Diabetologia 2000, 43:148-155.
41. Consultation WHOE Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363:157-163. the WHO Expert Consultation.
42. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol 2013, 108:1299-1304.
43. Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis 2010, 28:267-273.
44. Rabl C, Campos GM The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis 2012, 32:80-91.
45. Trayhurn P Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev 2013, 93:1-21.
46. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
47. Turer AT, Browning JD, Ayers CR, et al. Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study. J Clin Endocrinol Metab 2012, 97:E982-E986.
48. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
49. Turer AT, Scherer PE Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012, 55:2319-2326.
50. Machado MV, Cortez-Pinto H Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012, 11:440-449.
51. Frayn KN Visceral fat and insulin resistance-causative or correlative?. Br J Nutr 2000, 83(suppl 1):S71-S77.
52. Seidell JC, Bouchard C Visceral fat in relation to health: is it a major culprit or simply an innocent bystander?. Int J Obes Relat Metab Disord 1997, 21:626-631.
53. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009, 106:15430-15435.
54. Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 2010, 139:448-455.
55. Bray GA, Nielsen SJ, Popkin BM Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004, 79:537-543.
56. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011, 364:2392-2404.
57. de Koning L, Malik VS, Kellogg MD, Rimm EB, Willett WC, Hu FB Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men. Circulation 2012, 125:1735-1741.
58. Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, Hu FB Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care 2010, 33:2477-2483.
59. Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr 2009, 89:1037-1042.
60. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1961-1971. the Nonalcoholic Steatohepatitis Clinical Research Network.
61. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2013, published online Dec 4. 10.1053/j.gastro.2013.11.049.
62. Aarsland A, Wolfe RR Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men. J Lipid Res 1998, 39:1280-1286.
63. Kotronen A, Seppänen-Laakso T, Westerbacka J, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009, 58:203-208.
64. Westerbacka J, Kotronen A, Fielding BA, et al. Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. Gastroenterology 2010, 139:1961-1971.
65. Neuschwander-Tetri BA Carbohydrate intake and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2013, 16:446-452.
66. Sevastianova K, Santos A, Kotronen A, et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 2012, 96:727-734.
67. Mensink RP, Zock PL, Kester AD, Katan MB Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003, 77:1146-1155.
68. Soman VR, Koivisto VA, Deibert D, Felig P, DeFronzo RA Increased insulin sensitivity and insulin binding to monocytes after physical training. N Engl J Med 1979, 301:1200-1204.
69. Bae JC, Suh S, Park SE, et al. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS One 2012, 7:e46819.
70. Johnson NA, Keating SE, George J Exercise and the liver: implications for therapy in fatty liver disorders. Semin Liver Dis 2012, 32:65-79.
71. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012, 55:1738-1745.
72. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009, 136:1552-1560.
73. Rabøl R, Petersen KF, Dufour S, Flannery C, Shulman GI Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci USA 2011, 108:13705-13709.
74. Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009, 136:1585-1592.
75. Makkonen J, Pietiläinen KH, Rissanen A, Kaprio J, Yki-Järvinen H Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol 2009, 50:1035-1042.
76. Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005, 41:372-379.
77. Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, et al. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care 2006, 29:685-691.
78. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011, 7:e1001324. the NASH CRN, the GIANT Consortiumthe GIANT Consortium, the MAGIC Investigatorsthe MAGIC Investigators, the GOLD Consortiumthe GOLD Consortium.
79. Chambers JC, Zhang W, Sehmi J, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 2011, 43:1131-1138. the Alcohol Genome-wide Association (AlcGen) Consortium, the Diabetes Genetics Replication and Meta-analyses (DIAGRAM+) Studythe Diabetes Genetics Replication and Meta-analyses (DIAGRAM+) Study, the Genetic Investigation of Anthropometric Traits (GIANT) Consortiumthe Genetic Investigation of Anthropometric Traits (GIANT) Consortium, the Global Lipids Genetics Consortiumthe Global Lipids Genetics Consortium, the Genetics of Liver Disease (GOLD) Consortiumthe Genetics of Liver Disease (GOLD) Consortium, the International Consortium for Blood Pressure (ICBP-GWAS)the International Consortium for Blood Pressure (ICBP-GWAS), the Meta-analyses of Glucose and Insulin-Related Traits Consortium (MAGIC)the Meta-analyses of Glucose and Insulin-Related Traits Consortium (MAGIC).
80. Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012, 55:781-789.
81. Hernaez R, McLean J, Lazo M, et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol 2013, 11:1183-1190.
82. Palmer ND, Musani SK, Yerges-Armstrong LM, et al. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. Hepatology 2013, 58:966-975.
83. Gorden A, Yang R, Yerges-Armstrong LM, et al. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Hum Hered 2013, 75:34-43. the GOLD Consortium.
84. Norris JM, Rich SS Genetics of glucose homeostasis: implications for insulin resistance and metabolic syndrome. Arterioscler Thromb Vasc Biol 2012, 32:2091-2096.
85. Jean-Louis G, Zizi F, Clark LT, Brown CD, McFarlane SI Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med 2008, 4:261-272.
86. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 2013, 14:417-431.
87. Sookoian S, Pirola CJ Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg 2013, 23:1815-1825.
88. Sun K, Tordjman J, Clément K, Scherer PE Fibrosis and adipose tissue dysfunction. Cell Metab 2013, 18:470-477.
89. Huang G, Coviello A Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2012, 19:512-519.
90. Jones H, Sprung VS, Pugh CJ, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 2012, 97:3709-3716.
91. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
92. Sookoian S, Pirola CJ Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53:1883-1894.
93. Anstee QM, Day CP The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013, 10:645-655.
94. Li Y, Xing C, Tian Z, Ku HC Genetic variant I148M in PNPLA3 is associated with the ultrasonography-determined steatosis degree in a Chinese population. BMC Med Genet 2012, 13:113.
95. Peng XE, Wu YL, Lin SW, Lu QQ, Hu ZJ, Lin X Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. PLoS One 2012, 7:e50256.
96. Lin YC, Chang PF, Chang MH, Ni YH A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr 2013, 97:326-331.
97. Cox AJ, Wing MR, Carr JJ, et al. Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus. Diabetes Metab 2011, 37:452-455.
98. Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009, 58:2616-2623.
99. Huang Y, He S, Li JZ, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA 2010, 107:7892-7897.
100. Huang Y, Cohen JC, Hobbs HH Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011, 286:37085-37093.
101. Kumari M, Schoiswohl G, Chitraju C, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012, 15:691-702.
102. Romeo S, Sentinelli F, Dash S, et al. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond) 2010, 34:190-194.
103. Petit JM, Guiu B, Masson D, et al. Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab 2010, 95:E430-E436.
104. Li X, Zhao Q, Wu K, Fan D I148M variant of PNPLA3 confer increased risk for nonalcoholic fatty liver disease not only in European population, but also in Chinese population. Hepatology 2011, 54:2275.
105. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009, 50:2111-2116.
106. Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52:1274-1280.
107. Krarup NT, Grarup N, Banasik K, et al. The PNPLA3 rs738409 G-allele associates with reduced fasting serum triglyceride and serum cholesterol in Danes with impaired glucose regulation. PLoS One 2012, 7:e40376.
108. Kitamoto T, Kitamoto A, Yoneda M, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 2013, 132:783-792.
109. Palmer CN, Maglio C, Pirazzi C, et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One 2012, 7:e39362.
110. Hyysalo J, Gopalacharyulu P, Bian H, et al. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. Diabetes 2014, 63:312-322.
111. Lallukka S, Sevastianova K, Perttilä J, et al. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia 2013, 56:886-892.
112. Wang CW, Lin HY, Shin SJ, et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int 2011, 31:1326-1331.
113. Sevastianova K, Kotronen A, Gastaldelli A, et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 2011, 94:104-111.
114. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
115. Magkos F, Fabbrini E, McCrea J, Patterson BW, Eagon JC, Klein S Decrease in hepatic very-low-density lipoprotein-triglyceride secretion after weight loss is inversely associated with changes in circulating leptin. Diabetes Obes Metab 2010, 12:584-590.